Top

World Journal of Urology

Published in:

01-08-2016 | Topic Paper

Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patients

Authors: Y. A. M. Kuijpers, R. P. Meijer, G. N. Jonges, J. de Jong, J. L. H. R. Bosch, S. Horenblas, A. Bex

Published in: World Journal of Urology | Issue 8/2016

Abstract

Purpose

Guidelines recommend risk-adapted follow-up (FU) strategies after (partial) nephrectomy in non-metastatic renal cell carcinoma (RCC). Since current systemic therapy does not cure metastatic RCC, only timely detected recurrence accessible for local therapy is potentially curable. This study analyzed the rate and management of potentially curable recurrences per risk group.

Methods

This is a retrospective study including non-metastatic RCC patients who underwent (partial) nephrectomy from 2004 to 2011, with a minimum follow-up of 4 years. Risk stratification was by Leibovich score (clear cell subtype) and UICC/AJCC grading (other subtypes). Recurrence, time to recurrence, symptoms and detection method were documented. Isolated local recurrence, solitary- and oligometastases (≤3 lesions, single site) were considered potentially curable.

Results

Among 234 patients, followed during a median of 61.9 months, 68 patients (29.1 %) developed a recurrence of which 28 (41.2 %) were considered potentially curable. The 5-year risk of recurrence for low-, intermediate- and high-risk patients was 7.8, 26.3 and 59.1 % of which 71.4, 52.2 and 23.1 % were considered potentially curable, respectively. In high-risk patients, incurable recurrence was detected after a median of 7.9 (3.7–17.2) months versus 13.9 (6–41.3) months for potentially curable lesions. Only 13 of potentially curable lesions (46 %) received local therapy.

Conclusion

FU protocols should be adapted to the recurrence pattern of potentially curable disease. Most of the benefit may be achieved in intermediate-risk and high-risk-patients free of recurrence 1 year after surgery. Despite frequent imaging, only 13 patients (5.6 % of all patients followed) were managed with local therapy of whom only 4 remained free of disease.

Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Leibovich BC, Zincke H (2003) A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 170(6 Pt 1):2225–2232. doi:10.1097/01.ju.0000095541.10333.a7 CrossRefPubMed

Lam JS, Leppert JT, Figlin RA, Belldegrun AS (2005) Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 6(1):7–18CrossRefPubMed

Antonelli A, Cozzoli A, Zani D, Zanotelli T, Nicolai M, Cunico SC, Simeone C (2007) The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 99(2):296–300CrossRefPubMed

van Oostenbrugge TJ, Kroeze SG, Bosch JL, van Melick HH (2015) The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma. World J Urol 33(6):881–887. doi:10.1007/s00345-014-1390-6 CrossRefPubMed

Breau RH, Blute ML (2010) Surgery for renal cell carcinoma metastases. Curr Opin Urol 20(5):375–381CrossRefPubMed

Ljungberg B (2013) The role of metastasectomy in renal cell carcinoma in the era of targeted therapy. Curr Urol Rep 14(1):19–25CrossRefPubMed

Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, Staehler M, Powles T, Ljungberg B, Bex A (2014) Local treatments for metastases of renal-cell carcinoma: a systematic review. Lancet Oncol 15(12):e549–e561CrossRefPubMed

Klatte T, Lam JS, Shuch B, Belldegrun AS, Pantuck AJ (2008) Surveillance for renal cell carcinoma: why and how? When and how often? Urol Oncol 26(5):550–554. doi:10.1016/j.urolonc.2007.05.026 CrossRefPubMed

Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Herrell SD 3rd, Hilton S, Jonasch E, Lin DW, Reuter VE, Chang SS (2013) Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 190(2):407–416. doi:10.1016/j.juro.2013.04.121 CrossRefPubMed

10.

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924. doi:10.1016/j.eururo.2015.01.005 CrossRefPubMed

11.

Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, Kuan J, Brock GB, Tanguay S (2004) Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172(1):58–62. doi:10.1097/01.ju.0000132126.85812.7d CrossRefPubMed

12.

Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7):1663–1671CrossRefPubMed

13.

Siddiqui SA, Frank I, Cheville JC, Lohse CM, Leibovich BC, Blute ML (2009) Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int 104(6):778–785. doi:10.1111/j.1464-410X.2009.08499.x CrossRefPubMed

14.

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068CrossRefPubMed

15.

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265. doi:10.1002/cncr.25219 CrossRefPubMed

16.

Martinez-Salamanca JI, Huang WC, Millan I, Bertini R, Bianco FJ, Carballido JA, Ciancio G, Hernandez C, Herranz F, Haferkamp A, Hohenfellner M, Hu B, Koppie T, Martinez-Ballesteros C, Montorsi F, Palou J, Pontes JE, Russo P, Terrone C, Villavicencio H, Volpe A, Libertino JA (2011) Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol 59(1):120–127. doi:10.1016/j.eururo.2010.10.001 CrossRefPubMed

17.

Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P (2013) The international society of urological pathology (ISUP) vancouver classification of renal neoplasia. Am J Surg Pathol 37(10):1469–1489. doi:10.1097/PAS.0b013e318299f2d1 CrossRefPubMed

18.

Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663CrossRefPubMed

19.

Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882CrossRefPubMed

20.

Stewart SB, Thompson RH, Psutka SP, Cheville JC, Lohse CM, Boorjian SA, Leibovich BC (2014) Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. J Clin Oncol 32(36):4059–4065. doi:10.1200/jco.2014.56.5416 CrossRefPubMedPubMedCentral

21.

Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue B, Sharma P, Spiess PE, Poch MA, Pow Sang J, Sexton WJ (2015) Surveillance following nephron-sparing surgery: an assessment of recurrence patterns and surveillance costs. Urology 86(2):321–326. doi:10.1016/j.urology.2015.05.013 CrossRefPubMed

22.

Brookman-May SD, May M, Shariat SF, Novara G, Zigeuner R, Cindolo L, De Cobelli O, De Nunzio C, Pahernik S, Wirth MP, Longo N, Simonato A, Serni S, Siracusano S, Volpe A, Morgia G, Bertini R, Dalpiaz O, Stief C, Ficarra V (2013) Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma–results from a comprehensive multi-centre database (CORONA/SATURN-Project). BJU Int 112(7):909–916. doi:10.1111/bju.12246 PubMed

23.

Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Rehak P, Pummer K, Zigeuner R (2011) External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol 186(5):1773–1777. doi:10.1016/j.juro.2011.07.034 CrossRefPubMed

24.

Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS (2005) Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174(2):466–472; discussion 472; quiz 801. doi:10.1097/01.ju.0000165572.38887.da

25.

Beisland C, Gudbrandsdottir G, Reisaeter LA, Bostad L, Wentzel-Larsen T, Hjelle KM (2015) Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma. Scand J Urol 49(3):205–210. doi:10.3109/21681805.2014.980844 CrossRefPubMed

26.

Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980CrossRefPubMed

27.

Meimarakis G, Angele M, Staehler M, Clevert DA, Crispin A, Ruttinger D, Lohe F, Preissler G, Hatz RA, Winter H (2011) Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg 202(2):158–167CrossRefPubMed

28.

Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin RA, Belldegrun AS (2003) Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 61(2):314–319CrossRefPubMed

29.

Abdollah F, Suardi N, Capitanio U, Matloob R, Fossati N, Castiglione F, Di Trapani E, Di Trapani D, Russo A, Carenzi C, Montorsi F, Rigatti P, Bertini R (2014) The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: conditional survival analysis. Urol Oncol. doi:10.1016/j.urolonc.2013.05.006

30.

Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schildberg FW, Fuerst H (2002) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 73(4):1082–1087CrossRefPubMed

Title: Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patients
Authors: Y. A. M. Kuijpers
R. P. Meijer
G. N. Jonges
J. de Jong
J. L. H. R. Bosch
S. Horenblas
A. Bex
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 8/2016
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1822-6

At a glance: The STEP trials

Springer Medicine

Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patients

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2016

Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy

Percutaneous nephrolithotomy for staghorn stones: Which nomogram can better predict postoperative outcomes?

Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System

Cost-effectiveness of robot-assisted partial nephrectomy for the prevention of perioperative complications

Adherence to guideline recommendations for management of clinical T1 renal cancers in the Netherlands: a population-based study

A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use